Nadixa (Nadifloxacin)

Nadixa is indicated for bacterial skin conditions where topical antibacterial action is required.

• Acne vulgaris: reduces inflammatory lesions and bacterial colonisation on the skin.
• Secondary bacterial skin infections: treats infection of compromised skin caused by susceptible bacteria.
• Post‑procedural skin inflammation: helps prevent bacterial overgrowth after dermatologic procedures.

• Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and transcription. By blocking these targets, the drug prevents bacterial cell division and leads to bacterial cell death, providing a bactericidal effect against susceptible Gram‑positive and Gram‑negative organisms.

Nadixa may cause local and systemic adverse reactions.

Common Side Effects

• Skin irritation: mild redness or itching at the application site.
• Dryness: localized skin dryness or peeling.
• Burning sensation: transient burning feeling after application.
• Pruritus: occasional itching of the treated area.
• Erythema: mild redness of the skin.

Serious or Rare Side Effects

• Allergic reaction: rash, swelling, or hives indicating hypersensitivity.
• Stevens‑Johnson syndrome: rare severe skin reaction requiring immediate medical attention.
• Toxic epidermal necrolysis: extremely rare, life‑threatening skin detachment.
• Photosensitivity: increased sensitivity to sunlight leading to severe sunburn.
• Systemic absorption effects: rare systemic fluoroquinolone‑related events such as tendonitis.

When using Nadixa, consider the following safety measures.

• Contraindication: Do not apply to patients with known hypersensitivity to nadifloxacin or other fluoroquinolones.
• Pregnancy: Use only if the prescriber determines potential benefit outweighs risk; safety data are limited.
• Breastfeeding: Caution advised; discuss with a healthcare professional before use.
• Extensive skin damage: Avoid use on large areas of damaged or ulcerated skin.
• Sun exposure: Advise patients to limit UV exposure and use sunscreen on treated areas.
• Store below 25°C: keep in the original packaging, protect from moisture and light.

Nadixa may interact with other agents applied to the skin or systemic fluoroquinolones.

Major Interactions (Avoid)

• Systemic fluoroquinolones: concurrent use may increase risk of systemic toxicity.
• Topical corticosteroids: may reduce antibacterial efficacy and increase irritation.

Moderate Interactions (Monitor Closely)

• Other topical antibiotics: assess for additive irritation or resistance.
• Photosensitizing agents: monitor for enhanced photosensitivity reactions.
• Antacids or mineral supplements: unlikely with topical use but consider if systemic absorption occurs.